Reduced argatroban doses after coronary artery bypass graft surgery

Annals of Pharmacotherapy

Volumn 42, Issue 3, 2008, Pages 309-316

  Hoffman, William D ^a   Czyz, Yvonne ^a,b   McCollum, David A ^c   Hursting, Marcie J ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c CTI Clinical Trial and Consulting Services   (United States)

^d Clinical Science Consulting   (United States)

Author keywords

Argatroban; Coronary artery bypass graft; Heparin induced thrombocytopenia

Indexed keywords

ARGATROBAN; BILIRUBIN; CREATININE; HEPARIN; NITROGEN; UREA;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG FATALITY; FEMALE; FINGER AMPUTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION TEST; LABORATORY DIAGNOSIS; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE CARE; POSTOPERATIVE THROMBOSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; CORONARY ARTERY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 41149173180     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K434     Document Type: Article

References (30)

1. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg 2003;76:2121-31. DOI 10.1016/j.athoracsur.2003.09.034
2. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Grual Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005;128:837-41.
3. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004;164:361-9. DOI 10.1001/archinte.164.4.361
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 suppl):311S-37S. DOI 10.1378/chest.126.3_suppl.311s
5. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006;133:259-69. DOI 10.1111/j.1365-2141.2006. 06018.x
6. Package insert. Argatroban Injection. Research Triangle Park, NC: GlaxoSmithKline, July 2005.
7. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-43.
8. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-56. DOI 10.1001/archinte.163.15.1849
9. Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-84. DOI 10.1002/ccd.10276
10. Matthai WH, Hursting MJ, Lewis BE, Kelton JG. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005;116:121-6. DOI 10.1016/j.thromres.2004.11.006
11. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-29. DOI 10.1592/phco.20.4.318.34881
12. Levine R, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006;129;1167-75. DOI 10.1378/chest.129.5.1167
13. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409-14. DOI 10.1592/phco.24.4.409.33168
14. Reichert MG, MacGregor DA, Kincaid EH, Dolinski SY. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003;37:652-4. DOI 10.1345/aph.1C187
15. Begelman SM, Baghdasarian SB, Singh IM, Militello MA, Hursting MJ, Bartholomew JR. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intensive Care Med 2008, in press.
16. de Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 2003;37:1237-40. DOI 10.1345/aph.1C493
17. Beiderlinden M, Treschan TA, Görlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007;41:749-54. Epub 2007 Apr 17. DOI 10.1345/aph.1H569
18. Lubenow N, Selleng S, Wollert HG, Eichler P, Mullejans B, Greinacher A. Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use. Ann Thorac Surg 2003;75:577-9. DOI 10.1016/S0003-4975(02)04309-6
19. Koster A, Buz S, Hetzer R, Kuppe H, Breddin K, Harder S. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 2006;132:699-700. DOI 10.1016/j.jtcvs.2006.04.034
20. Cormack GM, Kaufman LJ. Severe heparin-induced thrombocytopenia: when the obvious is not obvious, a case report. J Med Case Reports 2007;1:13. DOI 10.1186/1752-1947-1-13
21. Ichikawa M, Oue M, Okamoto A, et al. A case of heparin-induced thrombocytopenia associated with unexpected excessive argatroban anticoagulation after abdominal aortic aneurysm resection. Masui 2006;55:188-92.
22. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006;4:759-65. DOI 10.1111/j.1538-7836.2006.01787.x
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
24. Arpino PA, Hallisey RK. Effect of renal function on the pharmacodynamics of argatroban. Ann Pharmacother 2004;38:25-9. DOI 10.1345/aph.1D163
25. Smythe MA, Stephens JL, Koerber JM, Mattson JC. A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost 2005;11:371-4. DOI 10.1177/107602960501100403
26. Kiser TH, Jung R, MacLaren R, Fish DN. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005;25:1736-45. DOI 10.1592/phco.2005.25.12. 1736
27. Kodityal S, Nguyen PH, Kodityal A, Sherer J, Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006;21:86-92. DOI 10.1177/0885066605284590
28. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007;24:489-99. DOI 10.2165/00002512-200724060-00005
29. Guzzi LM, Hursting MJ, McCollum DA. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006;22:169-76. DOI 10.1007/s11239-006-9019-2
30. Koster A, Hentschel T, Groman T, et al. Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery. J Thorac Cardiovasc Surg 2007;133:1376-7. DOI 10.1016/j.jtcvs.2007.01.008